Tradestie Institutional Equity Comparison Engine

NVO vs MBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

NVO Overall Edge

NVO Captures Institutional Edge (4โ€“0 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Novo-Nordisk A/S (NVO) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, NVO trades at 12.5x Forward P/E with 50.8% operating margin (+5.6% YoY revenue) versus MBIO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, NVO sits in CONSOLIDATION (32nd %ile IV; Dealer Gamma Walls on Pro) against MBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner NVO
NVO 12.5x vs MBIO N/M Fwd P/E
Growth & Margin Winner NVO
Op Margin 50.8% vs 0.0% ยท YoY +5.6% vs +0.0%
Momentum & Technical Winner NVO
1Y -15.4% vs -68.4% ยท 52W Pos 22% vs 3%
Options & Structure Winner NVO
CONSOLIDATION (32nd %ile IV) vs UNCLASSIFIED (N/A IV)
NVO NYSE
Novo-Nordisk A/S
Pharmaceutical Preparations
$41.60
-0.07% 1D
Market Cap $183.5B
1M Return +7.13%
1Y Return -15.38%
Forward P/E 12.5x
Unified AI Score
35.1 / 100 SELL
Tech 37.0 Fund 48.0 Flow 58.0 Mom 50.0
MBIO NASDAQ
Mustang Bio, Inc.
Pharmaceutical Preparations
$0.39
-2.46% 1D
Market Cap $3.2M
1M Return +3.22%
1Y Return -68.44%
Forward P/E N/M
Unified AI Score
42.9 / 100 HOLD
Tech 40.0 Fund 49.0 Flow 50.0 Mom 70.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NVO -15.38% MBIO -68.44% Spread: +53.85 pp (NVO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
NVO TTM Op. Margin: 50.8% MBIO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVO vs MBIO. Trailing 12-month operating profitability (NVO 50.8% vs MBIO 0.0%) and valuation multiples (NVO 12.5x vs MBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NVO (9) vs MBIO (1)
Institutional Metric NVO MBIO Criterion Row Winner
Market Capitalization Scale $183.5B $3.2M Larger Scale NVO
Trailing P/E Ratio Valuation 10.5x N/M Lower Multiple NVO
Forward P/E Ratio Valuation 12.5x N/M Lower Multiple NVO
Revenue Growth (YoY) Growth +5.6% +0.0% Higher Growth NVO
Operating Margin (TTM) Profitability 50.8% 0.0% Higher Margin NVO
Net Profit Margin Profitability 33.9% 0.0% Higher Margin NVO
Return on Equity (ROE) Capital Efficiency 58.4% -43.1% Higher ROE NVO
52-Week Range Position Momentum 22% ($35โ€“$64) 3% ($0โ€“$1) Stronger Trend NVO
Beta / 30D Volatility Risk Regime 0.50ฮฒ ยท 32% Vol 0.68ฮฒ ยท 87% Vol Lower Realized Risk NVO
Unified Institutional Score Composite Signal 35.1 / 100 (SELL) 42.9 / 100 (HOLD) Higher Composite MBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NVO vs MBIO Buy Guide
NVO CONSOLIDATION
95d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 32nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live NVO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MBIO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NVO nor MBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.